Brief: Crescita Therapeutics says evaluating strategic merger and acquisition opportunities
07/03/2016 12:15
March 7 (Reuters) - Crescita Therapeutics Inc CTX.TO : * Provides corporate update * Says is evaluating strategic merger and acquisition opportunities to grow its commercial product portfolio * Expects to receive feedback from FDA in Q2 on clinical,regulatory requirements for development of flexicaine * Will be finalizing its strategy for commercialization of pliaglis which is approved for sale in Canada,US Source text for Eikon urn:newsml:reuters.com:*:nPn5MM6g8 Further company coverage CTX.TO ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Crescita Therapeutics
See all newsBrief: Crescita Therapeutics Obtains Shareholder Approval To Be Acquired By Clinactiv Holdings
Canada's Crescita Q1 revenue rises on manufacturing growth
Canada's Crescita Q4 revenue falls on prior-year one-time reimbursement
Brief: Crescita Reports Q4 And Fiscal 2025 Results
Brief: Crescita Announces Definitive Agreement To Be Acquired By Clinactiv Holdings In An All-Cash Transaction At A Significant Premium